Genmab A/S Announces Share Capital Expansion
6-K: Report of foreign private issuer (related to financial reporting)
J&J Submits Supplemental BLA for Darzalex Faspro to FDA
Is Genmab A/S (GMAB) One of the Best Revenue Growth Stocks to Buy According to Analysts?
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $31
U.S. stock prospects | Wall Street sings praises! Tesla soared nearly 5%, reaching a two-month high; Chinese concept stocks stepping on the gas? Alibaba's stock price hits a one-year high, ke holdings skyrocketed by over 7% overnight.
Up more than 120% year-to-date! Sea rose more than 10% on the 3rd day, with many major banks setting a high target price of $96; the two-year cumulative increase is as high as 490%! Palantir's overnight stock price hit another record high, rising more than 25% since its inclusion in the s&p 500 index announcement.
Jin Medical International, Nio And Other Big Stocks Moving Lower In Monday's Pre-Market Session
HC Wainwright & Co. Reiterates Buy on Genmab, Maintains $50 Price Target
Strong Financials and Pipeline Promise Affirm Buy Rating for Genmab A/S
Genmab A/S (0MGB) Gets a Buy From UBS
Genmab Reports 'Encouraging Response Rate' From Investigational Ovarian Cancer Treatment Trial
Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients With Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial
Genmab Price Target Maintained With a $50.00/Share by HC Wainwright & Co.
H.C. Wainwright Maintains Genmab(GMAB.US) With Buy Rating, Maintains Target Price $50
H.C. Wainwright analyst Ram Selvaraju maintains $Genmab(GMAB.US)$ with a buy rating, and maintains the target price at $50.According to TipRanks data, the analyst has a success rate of 40.8% and a
Optimistic Buy Rating for Genmab on Promising Acasunlimab Clinical Data and Future Growth Potential
Genmab Announces Strategic Financial Updates
6-K: Report of foreign private issuer (related to financial reporting)
Morgan Stanley Maintains Equal-Weight on Genmab, Maintains $31 Price Target
Genmab Analyst Ratings